[1] 周丽萍,卓金樟.血液灌流联合常规透析对维持性血液透析伴高血压患者血压的影响[J].中外医疗,2021,40(14):64-66.
[2] 杨晓娜. 血液透析联合血液灌流治疗维持性血液透析合并难治性高血压的临床分析[J].中国医药指南,2020,18(15):136-137.
[3] 徐钢. 肾脏病诊疗指南[M].北京:北京科学出版社,2013,21-30.
[4] 冯婷婷,孙绘,吴晓霞,等.血液灌流联合黄芪注射液对维持性血液透析合并难治性高血压患者氧化应激、神经内分泌激素及生活质量的影响[J].现代中西医结合杂志,2018,27(17):1864-1867.
[5] Czerpak KF,Vergara EG,Cuadrado GB,et al.Usefulness of ABPM and bioimpedance for the treatment and control of hypertension in patients on chronic haemodialysis[J].Nefrologia,2021,41(1):17-26.
[6] 李瑞雪. 血液透析联合血液灌流治疗维持性血液透析患者合并难治性高血压的中长期疗效观察[J].中国社区医师,2017,33(13):30-32.
[7] 王超. 观察血液透析联合血液灌流治疗维持性血液透析患者顽固性高血压的临床效果[J].中国实用医药,2017,12(18):42-44.
[8] 张清生,伍军根,杨红霞.两种血液净化方式对维持性血液透析伴高血压患者的影响研究[J].中国当代医药,2020,27(7):72-74.
[9] 韦小红. 血液透析滤过与血液透析联合血液灌流治疗尿毒症顽固性高血压的疗效比较[J].医药前沿,2018,8(22):126-127.
[10] 谢治卿,贾婷,黄佑芳.血液透析与血液灌流联合治疗对维持性血液透析患者微炎症状态的影响[J].心血管病防治知识,2017,12(1):63-64.
[11] Sarafidis PA,Mallamaci F,Loutradis C,et al.Prevalence and control of hypertension by 48h ambulatory blood pressuremonitoring in haemodialysis patients:a study by the European Cardiovascular and Renal Medicine(EURECA - m)working group of the ERA - EDTA[J].phrol Dial Transplant,2019,34(9):1542-1548.
[12] Maruyama T,Takashima H,Abe M.Blood pressure targets and pharmacotherapy for hypertensive patients on hemodialysis[J].Expert OpinPharmacother,2020,21(10):1219-1240.
[13] Shaman AM,Smyth B,Arnott C,et al.Comparative Efficacy and Safety of BP - Lowering Pharmacotherapy in Patients Undergoing Maintenance Dialysis:A Network Meta -Analysis of Randomized,Controlled Trials[J].Clin J Am Soc Nephrol,2020,15(8):1129-1138 |
